Molecular Partners Ag (MOLN) Other Working Capital Changes (2021 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Other Working Capital Changes of $286.05 for Q1 2026, down 52.9% year-over-year from $607.29 in Q1 2025, and down 99.93% quarter-over-quarter from $418978.0 in Q4 2025.
Molecular Partners Ag (MOLN) Other Working Capital Changes (2021 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Other Working Capital Changes for 6 consecutive years, with $286.05 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Working Capital Changes fell 52.9% year-over-year to $286.05; the TTM figure through Mar 2026 stood at $416066.2 (up 55.53% YoY), while the FY2025 annual figure was $419141.9, up 54.93% from the prior year.
- Other Working Capital Changes declined to -$383.1 in Q1 2026 per MOLN's latest filing, from $757676.4 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $757676.4 in Q3 2025 and bottomed at -$732823.4 in Q2 2025.
- Historically, Other Working Capital Changes has averaged $4662.9 across 5 years, with a median of -$337.01 in 2025.
- On a YoY basis, Other Working Capital Changes climbed as much as 138.51% in 2022 and fell as far as 113.48% in 2022.
- Molecular Partners Ag's Other Working Capital Changes stood at $613103.2 in 2022, then advanced by 10.26% to $676010.6 in 2023, then rose by 2.8% to $694942.4 in 2024, then grew by 9.03% to $757676.4 in 2025, then sank by 100.05% to -$383.1 in 2026.
- Business Quant data shows MOLN's Other Working Capital Changes at -$383.1 in Q1 2026, $757676.4 in Q3 2025, and -$732823.4 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.57 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn |
| 4 | Moderna | 59.12 Bn | 53.98 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.75 Bn | 28.45 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.72 Bn | 668.28 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.20 Bn | 26.36 Bn | - |
| 10 | Molecular Partners Ag | 163.25 Mn | 163.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -383.10 |
| Mar 31, 2026 | -383.10 |
| Mar 31, 2026 | -383.10 |
| Sep 30, 2025 | 757,676.38 |
| Sep 30, 2025 | 757,676.38 |
| Sep 30, 2025 | 757,676.38 |
| Jun 30, 2025 | -732,823.38 |
| Jun 30, 2025 | -732,823.38 |
| Jun 30, 2025 | -732,823.38 |
| Mar 31, 2025 | -337.01 |
| Mar 31, 2025 | -337.01 |
| Mar 31, 2025 | -337.01 |
| Sep 30, 2024 | 694,942.41 |
| Sep 30, 2024 | 694,942.41 |
| Sep 30, 2024 | 694,942.41 |
| Jun 30, 2024 | -666,460.63 |
| Jun 30, 2024 | -666,460.63 |
| Jun 30, 2024 | -666,460.63 |
| Mar 31, 2024 | -344.85 |
| Mar 31, 2024 | -344.85 |